Internal Medicine

Investigators have found a pair of increased biomarker levels indicate patients with AF are at a greater risk of neurodegeneration.

The updated cholesterol guidelines continue to emphasize a healthy lifestyle for people of all ages and the need for personalized treatment plans. They also lay out a path for escalating treatment when statins aren’t sufficient.

A new meta-analysis finds people who were recently incarcerated face significantly higher risks of contracting hepatitis C and HIV infection.

A study of deep brain stimulation in patients with tardive dyskinesia and dystonia reports promising results.

Medical options can include oral contraceptives, pain medications, hormonal therapies, and gonadotropin-releasing hormone (GnRH) agonists.

A retrospective review finds HIV post-exposure prophylaxis is often prescribed outside of guidelines’ recommendations in response to patients' emotional stress.

A new study found that almost all humans have a less active form of interferon lambda 4, a fact that leaves them vulnerable to HCV.

The 4th generation VITROS Immunodiagnostic Products HIV Combo Reagent Pack and Calibrator has been approved by the FDA for use on the VITROS 5600 Integrated System.

When providers fail to recognize and combat stigma in their ranks, undiagnosed persons with HIV may go unidentified and fail to get quality care and treatment.

Cannabidiol (Epidiolex), the first FDA-approved plant-derived cannabinoid medicine in the United States, is now available by prescription for patients with seizures associated with Lennox-Gastaut syndrome or Dravet syndrome.

Combining glaucoma medications into a single eye drop could simplify regimens and reduce costs for patients. Investigators found that a combination eye drop also significantly reduced intraocular pressure compared to control.

CMS said it responded to complaints about its 2019 Medicare Physician Fee Schedule (PFS)—which it finalized today—and will not collapse 5 billing codes down to 2, which had drawn an outcry from some medical associations that their care for complex patients would be shortchanged.

How the therapy is proving capable of giving patients the opportunity to slow down disease progression, while potentially increasing the health outcomes of patients and saving money.

Martha L. Twaddle, MD, reviews new updates in the 4th edition of National Clinical Guidelines for Palliative Care.

Ronald Gentile, MD, and colleagues investigated pain-reduction strategies following intravitreal injections. The results have implications for patient experience, physician ratings, and treatment adherence.

Patients treated with faricimab every 16 weeks had a mean improvement of 11.4 letters from baseline, compared to 9.6 letters in those treated with ranibizumab every 4 weeks.

An anti-PIGF, a plasma kallikrein inhibitor, and a pan RGD integrin antagonist are some of the investigational treatments in the pipeline for diabetic retinopathy and diabetic macular edema.

David Brown, a retina specialist discusses how retina and diabetes specialists can coordinate care and education for their patients as well as the outlook for AMD/DME research.

In a phase 2 study, a long-acting, implantable delivery system for ranibizumab allowed patients with wet age-related macular degeneration to go up to 15 months before requiring a refill.

Hispanic/Latina women in the US access HIV treatment at same rates as men despite facing greater challenges.

Too few physicians have the “soft” communications and interpersonal skills they need to succeed in clinical settings. That’s a big and potentially deadly problem.

The SynchroMed II myPTM Personal Therapy Manager allows patients with chronic pain to manage unpredictable pain by delivering on-demand doses within limits set by their provider.

Switching antiepileptic drug manufacturer was found to increase the risk of seizure recurrence in a German population, contrary to findings in the US.

The investigators determined that hepatitis C co-infection increased risk for all-cause mortality in patients with HIV receiving antiretroviral treatment by 4.3%.

Only about half of people living with HIV who were released from prison or jail remained in HIV care 1-2 years after release.